SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?


To: Henry Niman who wrote (841)11/23/1998 11:21:00 AM
From: Alfredo Nova  Respond to of 965
 
To all: the recent sell-off in Centocor is unwarranted. I sold mine at 52 and just bought today at 44.
First Boston analyst Mr Schwartz has a excellent comment today and the paper on rheumatoid arthritis (Maini at al, 1998) clearly shows that antibodies are produced only at the very lowest dose. I believe the story remains very strong on Remicade and Reopro and that there is more to come in the future with antibodies to IL-6 and IL-12.
regards,
Alfredo Nova